This Contract Research Stock Rises 89% in 1 Year: What Is Driving the CRDMO Rally?

This contract research stock has nearly doubled investor money in the past twelve months, turning Rs 1 lakh into roughly Rs 1.89 lakh. One Hyderabad-based drug development partner delivered a 1-year return of 89.13% as of 10 September 2026, ranking 12th in a screen of 101 large-cap and mid-cap NSE shares.

The company is Sai Life Sciences Ltd (NSE: SAILIFE), a contract research, development and manufacturing organisation (CRDMO) that discovers, develops and produces drug molecules for global pharma innovators. The Sai Life Sciences share price moved from approximately Rs 845 a year ago to around Rs 1,598 on 10 September 2026, and the company is valued at approximately Rs 35,579 crore. The share listed only in December 2024, so this one-year run covers most of its life as a listed company.

Click Here – Get Free Investment Predictions

Which Contract Research Stock Rose 89% in 1 Year?

Sai Life Sciences is the contract research stock that rose approximately 89% in one year, placing it 12th out of 101 screened NSE stocks. The Sai Life Sciences share price traded near Rs 1,598 in the afternoon session on 10 September 2026, down about 4.6% from the previous close of Rs 1,675.40.

That fall came just days after a fresh record. The contract research stock touched a 52-week and lifetime high of Rs 1,697 during the week starting 7 September 2026, while its 52-week low stands at Rs 783.85, hit in early February 2026. Even after the day's drop, the contract research stock trades more than double its low point.

Period	Return	Rank (out of 101)
1 Month	12.52%	12
6 Months	62.75%	21
1 Year	89.13%	12
Since IPO (issue price Rs 549)	Approximately 191%	Not ranked

The table shows a steady, broad rally rather than a single spike. The contract research stock ranked 12th over both one month and one year, which suggests buying interest has stayed strong into September 2026. The IPO was priced at Rs 549 and the contract research stock listed at Rs 650 on NSE on 18 December 2024. Face value is Re 1 and there has been no split or bonus, so these returns reflect genuine price appreciation.

Why Did This Contract Research Stock Rally So Sharply?

The short answer: earnings grew far faster than revenue, big pharma clients handed over more work, and India's drug outsourcing theme gained momentum. The contract research stock also cleared a major supply overhang in August 2025, which set up the rally that followed.

1. Profit More Than Doubled in FY26

This contract research stock reported FY26 revenue growth of about 29%, EBITDA growth of about 56% and PAT growth of about 109%. Net profit rose to approximately Rs 349 crore from around Rs 170 crore in FY25. For a contract research stock, that kind of profit growth usually signals better plant use and a richer mix of work.

2. Margins Crossed 30% on a Full-Year Basis

Operating margin rose from around 16% in FY22 to approximately 31% in FY26. In Q3 FY26, reported EBITDA jumped 54% year-on-year to around Rs 191 crore and the margin expanded by roughly 605 basis points to about 34%. The contract research stock hit a record high of Rs 1,011.50 on 4 March 2026 soon after those numbers.

3. Big Pharma Is Moving More Work to India

For this contract research stock, large pharma clients made up about 49% of revenue in FY26, up from around 28% in FY22. The company serves 18 of the 25 largest biopharma companies by revenue, and the top 10 clients contribute about 54% of sales. The US BIOSECURE push to reduce reliance on Chinese suppliers has sent more enquiries to Indian partners, and this contract research stock is often cited as a key beneficiary.

4. Supply Overhang Cleared After TPG's Exit

On 26 August 2025, private equity investor TPG Asia sold about 3.07 crore shares, around 14.72% of the equity, at approximately Rs 874 per share. The contract research stock fell about 5% that day, but domestic and foreign institutions absorbed the supply. That exit removed a large seller from the register and changed the ownership mix sharply, as the shareholding table below shows.

5. Strong FY27 Visibility and a Sector Re-Rating

Management says over 90% of FY27 revenue is already covered by orders in hand, which gives this contract research stock rare visibility, with a revenue split of roughly 40:60 between H1 and H2. That implies 20%+ sales growth potential for the year. In early September 2026, the contract research stock gained about 8% in two days to a then-record Rs 1,578 while the Sensex fell, and it rallied around 80% over seven months.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Contract Research Stock Financials: Quarterly Trend

The quarterly numbers explain why investors pay up for this contract research stock. Profit has grown faster than sales in most quarters, although Q1 FY27 was seasonally softer than the March quarter.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Operating Margin	Net Profit (Rs Cr)	Net Margin
Jun 2025	506.32	130.83	26.36%	60.46	12.18%
Sep 2025	552.80	161.15	29.98%	83.84	15.60%
Dec 2025	564.84	196.24	33.77%	100.38	19.15%
Mar 2026	617.66	192.07	31.95%	104.24	17.28%
Jun 2026	557.83	151.55	27.34%	73.29	13.22%

In Q1 FY27, reported revenue from operations rose about 12% to around Rs 554 crore, EBITDA grew about 18% to around Rs 148 crore, and PAT rose about 22% to around Rs 73 crore. CRO revenue grew about 24% year-on-year, and CRO now contributes about 40% of sales while CDMO manufacturing contributes about 60%.

Management has guided for 15-20% revenue CAGR and EBITDA margins of 28-30% over the medium term, a target that keeps this contract research stock on growth investors' radar. Its commercial manufacturing pipeline includes 33 active commercial molecules and 14 late-phase molecules. A new 100,000 sq ft R&D facility at Genome Valley in Hyderabad became operational in the June 2026 quarter.

Annual Growth Since FY22

Revenue grew from approximately Rs 898 crore in FY22 to around Rs 2,242 crore in FY26, including other income. Net profit rose from roughly Rs 6 crore to approximately Rs 349 crore over the same period. Debt to equity fell from about 0.87 in FY24 to around 0.12 after the IPO money arrived, which gives the contract research stock a cleaner balance sheet to fund expansion.

Valuation of This Contract Research Stock

Metric	Value
Market Cap	Approximately Rs 35,579 Cr
PE Ratio (TTM)	Approximately 98
Industry PE	Approximately 38
Price to Book	Approximately 14.3
ROE	14.05%
Debt to Equity	0.12
EPS (TTM)	Rs 17.03
52-Week High / Low	Rs 1,697 / Rs 783.85

On these numbers, the contract research stock trades at roughly two and a half times the industry PE. ROE of around 14% is modest relative to that valuation, partly because the IPO raised fresh equity and heavy capex has not yet produced full returns. At the afternoon price of Rs 1,598, the trailing PE works out to approximately 94.

Investors are paying for future growth rather than current earnings. That can work if profit keeps compounding at 25-30% a year, but it leaves little room for a weak quarter.

Who Owns This Contract Research Stock?

Quarter	Promoters	FIIs	DIIs	Public
Jun 2025	35.15%	14.58%	21.64%	28.64%
Sep 2025	34.94%	22.50%	29.91%	12.65%
Dec 2025	34.70%	21.40%	31.41%	12.49%
Mar 2026	34.61%	21.17%	31.54%	12.68%
Jun 2026	34.53%	19.65%	32.71%	13.11%

The big shift came in the September 2025 quarter, when the public category fell from about 28.64% to around 12.65% after TPG's exit, while FIIs and DIIs together rose above 52%. Since then, DIIs have kept adding, climbing to about 32.71% by June 2026. FII holding has eased from its peak of 22.50% to around 19.65%, so foreign investors have booked some profit during the rally.

Promoter holding in the contract research stock has stayed near 34.5%, a relatively low level for an Indian mid-cap. Mutual funds such as healthcare, small-cap and mid-cap schemes hold the share, which adds depth but also means the contract research stock can react sharply to fund flows.

Key Risks for Investors

The rally has been strong, but this contract research stock carries real risks that investors should weigh before taking a position.

Rich valuation: For a contract research stock, a PE near 94-98 prices in years of strong growth. Any earnings miss or guidance cut could trigger a sharp correction, as seen in the 4.6% drop on 10 September 2026 and the dip after Q1 FY27 results despite a profit beat.

Heavy capex cycle: The company behind this contract research stock spent approximately Rs 633 crore on capex in FY26 and plans Rs 1,100-1,300 crore in FY27. Q1 FY27 capex alone was around Rs 263 crore, and capacity utilisation was about 65%. If new plants fill slowly, returns on capital could stay subdued.

Lumpy revenue and client concentration: Revenue at any contract research stock depends on molecule approvals and project timing. With the top 10 clients contributing about 54% of revenue, one delayed or failed programme can hurt a quarter. Management expects a 40:60 H1 to H2 split in FY27, so the second half must deliver.

Policy and global risk: The BIOSECURE tailwind depends on US policy, and the final version has been diluted from earlier drafts. Currency moves, geopolitical tension and input costs also feed into the business of any contract research stock serving overseas customers.

Download the Univest iOS App or Univest Android App to track the Sai Life Sciences share price live

Sai Life Sciences Share: Analyst View

Brokerages remain constructive on this contract research stock but divided on price after the rally. Most coverage highlights rising big pharma engagement, 90%+ FY27 revenue visibility and margin gains as the core reasons to own this contract research stock over the long term.

In March 2026, a domestic brokerage raised its earnings estimates by 13-17% and forecast revenue, EBITDA and PAT CAGR of 25%, 35% and 49% over two years. Analysts also flag that the Sai Life Sciences share price has run ahead of several published targets, so near-term upside may depend on fresh earnings upgrades.

Sai Life Sciences Share Price Target

A foreign brokerage has a Buy rating with a Sai Life Sciences share price target of Rs 1,610, roughly in line with the current price. The domestic brokerage set a Sai Life Sciences share price target of Rs 1,318 in March 2026, which the share has already crossed. Published consensus data shows an average Sai Life Sciences share price target of approximately Rs 1,275, in a range of Rs 1,225 to Rs 1,371, though several of those estimates predate the latest rally.

With the Sai Life Sciences share price trading near or above most targets, the 52-week high of Rs 1,697 acts as the immediate reference on the upside, while the Rs 1,450-1,500 zone, where the share consolidated in August 2026, is a level traders watch on the downside.

Conclusion

Sai Life Sciences has earned its place as a top-performing contract research stock, rising approximately 89% in a year on the back of doubled profit, 30%+ margins, deeper big pharma relationships and a cleaner shareholder register after TPG's exit. The Sai Life Sciences share price now reflects much of that progress.

The next leg for the contract research stock depends on execution: filling new capacity, delivering the heavier second half of FY27 and sustaining margins in the 28-30% band. For long-term investors, the business case is clear, but the valuation calls for patience, position sizing and a close watch on quarterly numbers rather than chasing the recent momentum.

Frequently Asked Questions

Which contract research stock rose 89% in 1 year?

Ans. Sai Life Sciences Ltd (NSE: SAILIFE) is the contract research stock that rose 89.13% in one year as of 10 September 2026. It ranked 12th among 101 screened NSE stocks, moving from around Rs 845 to approximately Rs 1,598.

What is the Sai Life Sciences share price today?

Ans. The Sai Life Sciences share price was around Rs 1,598 on 10 September 2026, down about 4.6% from the previous close of Rs 1,675.40. The 52-week range is Rs 783.85 to Rs 1,697.

Why did the Sai Life Sciences share rise so much?

Ans. The Sai Life Sciences share rose on a 109% jump in FY26 profit, operating margins above 30%, and more work from large global pharma clients. TPG's exit in August 2025 also cleared a major supply overhang as institutions absorbed the shares.

What is the analyst target for Sai Life Sciences?

Ans. A foreign brokerage has a target of Rs 1,610 with a Buy rating. A domestic brokerage set Rs 1,318 in March 2026, and the published consensus average is approximately Rs 1,275, below the current price.

What was the Sai Life Sciences IPO price?

Ans. The Sai Life Sciences IPO was priced at Rs 549 per share and listed on NSE at Rs 650 on 18 December 2024. At around Rs 1,598, the share trades approximately 191% above the issue price.

Is Sai Life Sciences overvalued?

Ans. The contract research stock trades at a trailing PE of approximately 94 to 98 against an industry PE near 38, so the valuation is demanding. It depends on sustained profit growth of 25% or more to justify that premium.

What does Sai Life Sciences do?

Ans. Sai Life Sciences is a Hyderabad-based contract research stock and CRDMO that offers drug discovery research, process development and commercial manufacturing to global pharma and biotech companies. CRO services contribute about 40% of revenue and CDMO manufacturing about 60%.

What are the main risks for Sai Life Sciences investors?

Ans. Key risks include a rich valuation, a heavy Rs 1,100-1,300 crore capex plan for FY27, lumpy project-based revenue and dependence on top clients. Changes in US policy on Chinese suppliers could also affect the outsourcing tailwind.